A873 POST SURVEY & EVAL - JAK/TYK2 Inhibition: New Frontiers in the Treatment of Psoriasis

PLEASE COMPLETE THIS POSTSURVEY AFTER THE PRESENTATION

Question Title

1. Which of the following is a JAK-mediated cytokine active in psoriasis? (Required.)

a. Erythropoietin (EPO)

b. IL-12

c. IL-17

d. TNF-alpha

Question Title

2. How confident are you that you selected the correct response for the previous question? (Required.)

a. Not at all confident

b. Somewhat confident

c. Confident

d. Very confident

Question Title

3. The results of the phase 2 trial of deucravacitinib (BMS-986165) in psoriasis show which of the following? (Required.)

a. Patients receiving deucravacitinib at least 3 mg/day achieved PASI75 and PASI90 at rates similar to those seen with biologics

b. Patients receiving deucravacitinib at least 3 mg/day achieved PASI75 and PASI90 scores that are greater than those seen with biologics

c. Patients receiving deucravacitinib at least 3 mg/day achieved PASI75 and PASI90 scores that are similar to responses seen with apremilast

d. Patients receiving deucravacitinib at least 3 mg/day achieved PASI75 and PASI90 scores at significantly greater rates than placebo but less than what is seen with biologics

Question Title

4. Which of the following is correct regarding the theoretical mechanistic safety of TYK2 inhibition compared with JAK inhibitors? (Required.)

a. TYK2 inhibition potentially reduces the likelihood of viral infections

b. TYK2 inhibition potentially reduces the likelihood of bacterial infections

c. TYK2 inhibition potentially reduces the likelihood of malignancy

d. TYK2 inhibition potentially reduces the likelihood of anemia

Question Title

5. How confident are you that you selected the correct response for the previous question? (Required.)

a. Not at all confident

b. Somewhat confident

c. Confident

d. Very confident

Question Title

6. Recent data from the POETYK-PSO-1 trial in psoriasis shows deucravacitinib was superior to placebo and which active comparator for PASI75 response at week 16? (Required.)

a. Adalimumab

b. Apremilast

c. Etanercept

d. Ustekinumab

Question Title

7. Francine is a 43-year-old woman with moderate to severe plaque psoriasis with nail involvement, and psoriatic arthritis involving her peripheral joints. Which of the following is likely to be most beneficial? (Required.)

a. Tildrakizumab

b. Guselkumab

c. Risankizumab

d. Tofacitinib

Question Title

* 1. Which of the following is a JAK-mediated cytokine active in psoriasis? (Required.)

Question Title

* 2. How confident are you that you selected the correct response for the previous question? (Required.)

Question Title

* 3. The results of the phase 2 trial of deucravacitinib (BMS-986165) in psoriasis show which of the following? (Required.)

Question Title

* 4. Which of the following is correct regarding the theoretical mechanistic safety of TYK2 inhibition compared with JAK inhibitors? (Required.)

Question Title

* 5. How confident are you that you selected the correct response for the previous question? (Required.)

Question Title

* 6. Recent data from the POETYK-PSO-1 trial in psoriasis shows deucravacitinib was superior to placebo and which active comparator for PASI75 response at week 16? (Required.)

Question Title

* 7. Francine is a 43-year-old woman with moderate to severe plaque psoriasis with nail involvement, and psoriatic arthritis involving her peripheral joints. Which of the following is likely to be most beneficial? (Required.)

Question Title

* 8. Please Indicate the Regional Meeting you attended (Select 1) (Required.)

1. Which of the following is a JAK-mediated cytokine active in psoriasis? (Required.)

2. How confident are you that you selected the correct response for the previous question? (Required.)

3. The results of the phase 2 trial of deucravacitinib (BMS-986165) in psoriasis show which of the following? (Required.)

4. Which of the following is correct regarding the theoretical mechanistic safety of TYK2 inhibition compared with JAK inhibitors? (Required.)

5. How confident are you that you selected the correct response for the previous question? (Required.)

6. Recent data from the POETYK-PSO-1 trial in psoriasis shows deucravacitinib was superior to placebo and which active comparator for PASI75 response at week 16? (Required.)

7. Francine is a 43-year-old woman with moderate to severe plaque psoriasis with nail involvement, and psoriatic arthritis involving her peripheral joints. Which of the following is likely to be most beneficial? (Required.)

8. Please Indicate the Regional Meeting you attended (Select 1) (Required.)